Drug Trial Radar · NCT04467060
A Single Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
Last checked: Nov 19, 2026Latest source record: Jul 10, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
74
Actual
Start
Aug 14, 2014
Primary completion
Jun 25, 2015
Study completion Jun 25, 2015
Sponsor
- Lead sponsor
- Sihuan Pharmaceutical Holdings Group Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 10, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A single-center, randomized, open-labeled, 2×2 crossover phase 1 study to evaluate the pharmakinetics effect of high fat food to single dose administration of Anaprazole in healthy Chinese male subjects. 14 health male subjects is divided to A group (n=7) and B group (n=7). 2 periods (7 days) cross-over design, anaprazole 40mg single dose, one is fasting oral administration before breakfast, the other is oral administration 30 minutes after breakfast with high fat food.
Conditions
- Healthy Male Volunteers
Interventions
Anaprazole SodiumDrug
2.5mg, 5mg, 10mg, 20mg, 40mg, 80mg, 120mg, 160mg,fasting oral administration.
PlaceboDrug
single dose, fasting oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjects with adverse events and serious adverse events as assessed by CTCAE v5.0Time frame: From signing informed consent to study completion, 8 days post-dose
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.